Amay Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 16.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 15.30 Cr
as on 09-12-2024
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2018
- Satisfied Charges ₹ 38.78 Cr
as on 09-12-2024
- Revenue -95.32%
(FY 2018)
- Profit 105.15%
(FY 2018)
- Ebitda 98.71%
(FY 2018)
- Net Worth 6.89%
(FY 2018)
- Total Assets -1.81%
(FY 2018)
About Amay Pharmaceuticals
The Corporate was formerly known as Aprica Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 16.00 Cr and a paid-up capital of Rs 15.30 Cr.
The company has closed loans amounting to ₹38.78 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jitendrakumar Rokad and Rinkubhai Trivedi serve as directors at the Company.
- CIN/LLPIN
U24230GJ2011PTC066787
- Company No.
066787
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Aug 2011
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Amay Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendrakumar Rokad  | Director | 16-Aug-2011 | Current |
| Rinkubhai Trivedi | Additional Director | 25-Jan-2019 | Current |
Financial Performance and Corporate Structure Insights of Amay Pharmaceuticals.
Amay Pharmaceuticals Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 95.32% decrease. The company also saw a substantial improvement in profitability, with a 105.15% increase in profit. The company's net worth moved up by a moderate rise of 6.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amay Pharmaceuticals?
In 2018, Amay Pharmaceuticals had a promoter holding of 58.33% and a public holding of 41.67%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Aprica Business Solutions Private LimitedActive 12 years 9 months
Jitendrakumar Rokad is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Kotak Mahindra Bank Limited Creation Date: 28 May 2014 | ₹3.98 Cr | Satisfied |
State Bank Of India Creation Date: 03 Jul 2012 | ₹16.40 Cr | Satisfied |
State Bank Of India Creation Date: 03 Jul 2012 | ₹16.40 Cr | Satisfied |
How Many Employees Work at Amay Pharmaceuticals?
Unlock and access historical data on people associated with Amay Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amay Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amay Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
